Raj Makkar
A5044531608- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Aortic Disease and Treatment Approaches
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Tissue Engineering and Regenerative Medicine
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrhythmias and Treatments
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Mechanical Circulatory Support Devices
- Venous Thromboembolism Diagnosis and Management
- Congenital Heart Disease Studies
- Electrospun Nanofibers in Biomedical Applications
- Mesenchymal stem cell research
- Pulmonary Hypertension Research and Treatments
- Cardiac and Coronary Surgery Techniques
- Cardiac Fibrosis and Remodeling
- Aortic aneurysm repair treatments
- Congenital heart defects research
- Cardiac Ischemia and Reperfusion
Cedars-Sinai Medical Center
2016-2025
Cedars-Sinai Smidt Heart Institute
2016-2025
Columbia University Irving Medical Center
2012-2024
NewYork–Presbyterian Hospital
2012-2024
Morristown Medical Center
2023-2024
Imaging Center
2020-2024
University Medical Center
2024
Medical University of Silesia
2024
Institute of Cardiology
2024
Poznan University of Medical Sciences
2024
Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the valve. Recently, transcatheter aortic-valve implantation (TAVI) has been suggested as a less invasive treatment high-risk stenosis.
The use of transcatheter aortic-valve replacement has been shown to reduce mortality among high-risk patients with aortic stenosis who are not candidates for surgical replacement. However, the two procedures have compared in a randomized trial involving still
Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar transcatheter aortic-valve replacement (TAVR) and surgical replacement. We evaluated the two procedures in a randomized trial involving intermediate-risk patients.
Among patients with aortic stenosis who are at intermediate or high risk for death surgery, major outcomes similar transcatheter aortic-valve replacement (TAVR) and surgical replacement. There is insufficient evidence regarding the comparison of two procedures in low risk.
The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that among high-risk patients with aortic stenosis, the 1-year survival rates are similar transcatheter aortic-valve replacement (TAVR) and surgical replacement. However, longer-term follow-up is necessary to determine whether TAVR has prolonged benefits.At 25 centers, we randomly assigned 699 severe stenosis undergo either or TAVR. All were followed for at least 2 years, assessment clinical outcomes echocardiographic...
Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates surgery. The outcomes beyond 1 year in such known.We randomly assigned to transfemoral TAVR or standard (which often included balloon valvuloplasty). Data on 2-year were analyzed.A total of 358 underwent randomization at 21 centers. rates death 2 years 43.3% group and 68.0% standard-therapy (P<0.001), corresponding cardiac 31.0% 62.4% (P<0.001)....
<h3>Objective.</h3> —To test the hypothesis that female prevalence is greater than expected among reported cases of torsades de pointes associated with cardiovascular drugs prolong cardiac repolarization. <h3>Data Sources.</h3> —A MEDLINE search English-language literature for period 1980 through 1992, using terms<i>torsade pointes, polymorphic ventricular tachycardia, atypical proarrhythmia</i>, and<i>drug-induced tachycardia</i>, supplemented by pertinent references (dating back to 1964)...
Smith, Craig R.*; Leon, Martin B.*; Mack, Michael J.†; Miller, D. Craig§; Moses, Jeffrey W.*; Svensson, Lars G.¶; Tuzcu, E. Murat¶; Webb, John G.#; Fontana, Gregory P.**; Makkar, Raj R.**; William, Mathew*; Dewey, Todd‡; Kapadia, Samir¶; Babaliaros, Vasilis††; Thourani, Vinod H.††; Corso, Paul‡‡; Pichard, Augusto D.‡‡; Bavaria, Joseph E.§§; Herrmann, Howard C.§§; Akin, Jodi J.∥; Anderson, William N.∥; Wang, Duolao∥∥; Pocock, Stuart J.∥∥ for the PARTNER (Placement of Aortic Transcatheter...
There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical in patients severe aortic stenosis intermediate risk.We enrolled 2032 intermediate-risk severe, symptomatic at 57 centers. Patients were stratified according to intended transfemoral or transthoracic access (76.3% 23.7%, respectively) randomly assigned undergo either TAVR replacement. Clinical, echocardiographic, health-status...
The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these for transcatheter surgical aortic valve trials. Rapid evolution the field, including emergence new complications, expanding indications, novel therapy strategies have mandated further refinement expansion ensure relevance. This document provides an update most endpoint be used conduct research.Several years after publication...
In patients with aortic stenosis (AS), risk stratification for valve replacement (AVR) relies mainly on valve-related factors, symptoms and co-morbidities. We sought to evaluate the prognostic impact of a newly-defined staging classification characterizing extent extravalvular (extra-aortic valve) cardiac damage among severe AS undergoing AVR.Patients from PARTNER 2 trials were pooled classified according presence or absence as detected by echocardiography prior AVR: no (Stage 0), left...
Severe tricuspid regurgitation is a debilitating condition that associated with substantial morbidity and often poor quality of life. Decreasing may reduce symptoms improve clinical outcomes in patients this disease.We conducted prospective randomized trial percutaneous transcatheter edge-to-edge repair (TEER) for severe regurgitation. Patients symptomatic were enrolled at 65 centers the United States, Canada, Europe randomly assigned 1:1 ratio to receive either TEER or medical therapy...